1 van Os J Kapur S. Schizophrenia. Lancet (2009) 374:635–45.10.1016/S0140-6736(09)60995-8 19700006

2 Wobrock T Weinmann S Falkai P Gaebel W. Schizophrenia treatment based on practice guidelines. Nervenheilkunde (2009) 28:448–55.

3 Konopka A Klingberg S Wittorf A König HH. The cost of schizophrenia in Germany: a systematic review of the literature. [Article in German]. Psychiatr Prax (2009) 36:211–8.10.1055/s-0028-1090234

4 Kerkemeyer L Mostardt S Biermann J Wasem J Neumann A Walendzik A Evaluation of an integrated care program for schizophrenia: concept and study design. Eur Arch Psychiatry Clin Neurosci (2014) 265:155–62.10.1007/s00406-014-0508-6

5 Weinmann S Roick C Martin L Willich S Becker T. Development of a set of schizophrenia quality indicators for integrated care. Epidemiol Psichiatr Soc (2010) 19:52–62.10.1017/S1121189X00001603 20486424

6 Kriz D Nübling R Steffanowski A Wittmann WW Schmidt J. Patients’ satisfaction in inpatient rehabilitation. Psychometrical evaluation of the ZUF-8 based on a multicenter sample of different indications. [Article in German]. Z Med Psychol (2008) 17:67–79.

7 Gaebel W Wölwer W. Gesundheitsberichterstattung des Bundes – Heft 50: Schizophrenie. Berlin: Robert Koch Institut (2010).

8 Oreski I Jakovljevic M Aukst-Margetic B Crncevic Olic Z Vuksan-Cusa B. Comorbidity and multimorbidity in patients with schizophrenia and bipolar disorder: similarities and differences. Psychiatr Danub (2012) 24:80–5.22447090

9 Craig TJ Fennig S Tanenberg-Karan M Bromet EJ. Rapid versus delayed readmission in first-admission psychosis: quality indicators for managed care? Ann Clin Psychiatry (2000) 12:233–8.10.3109/10401230009147117 11140925

10 Ganguly R Kotzan JA Miller LS Kennedy K Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry (2004) 65:1377–88.10.4088/JCP.v65n1013 15491242